#YearInReview: In matched-related donor stem cell transplantation, cyclophosphamide + calcineurin inhibition significantly improved GVHD- & relapse-free survival vs standard therapy—without added toxicity. From #EHA25
🔸 David Curtis, MBBS, PhD
🔗 https://ow.ly/ZfQ450XNJ1R

Check out what's new in the July issue! Highlights include a feature on the Trump administration's impact on #hematology in its first 100 days, testing and treatment of elevated factor levels post-stroke, recent findings from #ASCO25 and #EHA25, and more: ow.ly/Q9GR50WtAfN
#HemeSky #MedSky

Quizartinib Plus Chemotherapy Shows Strong Activity in FLT3-ITD–Positive, NPM1-Mutated AML FLT3-ITD positivity plus mutations in NPM1 and epigenetic regulatory genes led to heightened efficacy of quizartinib plus chemotherapy in newly diagnosed AML.

Quizartinib Plus Chemotherapy Shows Strong Activity in FLT3-ITD–Positive, NPM1-Mutated AML #EHA25 #leusm www.onclive.com/view/quizart...

What’s New in Myeloma Research? Join our speakers virtually on Tuesday, July 1 to hear about the top myeloma research presented at #ASCO25, #EHA25, and IMWG—from a patient perspective. Register NOW before spots are gone: https://mmsm.link/4kTQD1P

#IMFASCO #IMFEHA #IMFIMWG #mmsm

25 Posts Not to Miss from EHA 2025: - OncoDaily The European Hematology Association (EHA 2025) congress is officially underway in Milan. From June 12 to 15, hematology professionals from

25 Posts Not to Miss from EHA 2025
@nicogagelmann.bsky.social @talhabadarmd.bsky.social @majorajay.bsky.social @vincentrk.bsky.social @viveksubbiah.bsky.social @nejm.org

oncodaily.com/societies/eh...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #EHA2025 #EHA25

Ruben Mesa: Excited to be a co-investigator of the MANIFEST2 trial presented by Alessandro Vannucchi at EHA25 - OncoDaily Ruben Mesa: Excited to be a co-investigator of the MANIFEST2 trial presented by Alessandro Vannucchi at EHA25 / Alessandro Vannucchi, cancer, EHA25, MANIFEST2

Excited to be a co-investigator of the MANIFEST2 trial presented by Alessandro Vannucchi at EHA25 - Ruben Mesa
@rubenmesamd.bsky.social

oncodaily.com/blog/manifes...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #MANIFEST2 #EHA25

#EHA25: Gilead, Arcellx continue to tout safety of multiple myeloma cell therapy anito-cel Gilead and Arcellx reported that their multiple myeloma CAR-T therapy continued to show potentially better safety than Legend Biotech and Johnson & Johnson’s Carvykti, with comparable efficacy. With updated results for ...

Thoughts on this? >> #EHA25: Gilead, Arcellx continue to tout safety of multiple
myeloma cell therapy anito-cel >> Comment below! #strategy #competitiveintelligence #marketing #pharmaceutical #biotech #pharma #productmarketing #healthcare

J&J's next CAR-T contender shows near-universal responses in LBCL $JNJ #EHA25 firstwordpharma.com/story/5972830

JNJ’4496 Shows Preliminary Efficacy and Safety in Relapsed/Refractory LBCL JNJ’4496 demonstrated an ORR of 100% in patients with relapsed or refractory large B-cell lymphoma who received 1 prior line of treatment.

JNJ’4496 Shows Preliminary Efficacy and Safety in Relapsed/Refractory #LBCL #EHA25 #oncology

www.onclive.com/view/jnj-449...

Iptacopan Shows Efficacy Improvements Over Anti-C5 Therapy in Previously Treated Paroxysmal Nocturnal Hemoglobinuria Oral iptacopan monotherapy led to hemoglobin level and transfusion independence benefits vs anti-C5 therapies in paroxysmal nocturnal hemoglobinuria.

Iptacopan Shows Efficacy Improvements Over Anti-C5 Therapy in Previously Treated Paroxysmal Nocturnal Hemoglobinuria #EHA25 #hematology @kingscollegenhs.bsky.social
www.onclive.com/view/iptacop...

Ponatinib Is Associated With Improved Survival in Ph+ ALL With MRD Positivity After Induction A post hoc analysis of the PhALLCON showed response and survival benefits with imatinib in Ph-positive ALL with MRD negativity after induction.

Ponatinib Is Associated With Improved Survival in Ph+ #ALL With MRD Positivity After Induction #EHA25 #oncology

www.onclive.com/view/ponatin...

Hey from #EHA25 in Milan!👋 Stop by SOHO booth M17 (next to the Exhibitor Service Center) to say hi, pick up the latest SOHO Insider, & get the latest SOHO updates!

Note: SOHO is no longer affiliated with BCT.
#EHA2025 #MedSky #HemOnc

Folks at #EHA2025: check out our poster (PS1898) on PROs in EPCORE NHL-1. Patients with R/R FL who had 3+ symptoms at baseline had clinically-meaningful improvements in lymphoma-related symptoms that continued to improve after epco initiation. #EHA25 library.ehaweb.org/eha/2025/eha...

If you want to hear more from the authors of the first set of commission manuscripts, our @thelancethaem.bsky.social podcast is now online! www.buzzsprout.com/1564352/epis... ft @biostatgirl.bsky.social @broeckelmann.bsky.social #EHA2025 #EHA25

Currently at #EHA2025: @broeckelmann.bsky.social presenting our recent @thelancethaem.bsky.social commission on adverse events, starting with our paper (with @biostatgirl.bsky.social) on advancing the measurement & dissemination of AE data HT @eddiecliff.bsky.social #EHA25

Join us on sunday morning at #EHA25 for the EHA - EBMT Joint Symposium!

Yes, I know is early, but I’ll be sure to show you where the good coffee is 😜

First interview of the #EHA25 Day 2. Dr. Litzow of @MayoClinic #mmsm #allsm Remember stop by and share your research. Hearing about your research provides patients with hope. We are located across from Coral 4!

Venetoclax/DEC-C Is Potential New SOC in Newly Diagnosed AML Ineligible for Intensive Chemo OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Venetoclax/DEC-C Is Potential New SOC in Newly Diagnosed #AML Ineligible for Intensive Chemo #EHA25 #oncology

www.onclive.com/view/venetoc...

See the latest from #EHA25 on my heme/onc conference feed: bsky.app/profile/did:...

#EHA25: Kura, Kyowa say Phase 1 update supports menin inhibitor combos  As Kura Oncology and Kyowa Kirin await an FDA decision for their oral menin inhibitor in acute myeloid leukemia, the partners are highlighting another early cut of data for a combo with the drug in ...

Thoughts on this? >> #EHA25: Kura, Kyowa say Phase 1 update supports menin
inhibitor combos  >> Comment below! #strategy #competitiveintelligence #marketing #productmarketing #pharma #healthcare #biotech #pharmaceutical

FELIX post-hoc data reinforce obe-cel durability - SOHO Insider A post-hoc analysis found that the chimeric antigen receptor T-cell therapy obecabtagene autoleucel (obe-cel) produced durable remissions and maintained a favorable benefit-risk profile across all age...

FELIX post-hoc data reinforce obe-cel durability #EHA2025 #EHA25 #CART

sohoinsider.com/news/felix-p...

It should be an exciting session, hope to see you there! #EHA25

#EHA25: Schrödinger reports early Phase 1 data for MALT1 inhibitor Schrödinger said its experimental MALT1 inhibitor showed early signs of safety and efficacy in an ongoing Phase 1 trial. The company also said the data support its broader computational discovery platform, which allowed the team ...

Thoughts on this? >> #EHA25: Schrödinger reports early Phase 1 data for MALT1
inhibitor >> Comment below! #strategy #competitiveintelligence #marketing #pharma #biotech #productmarketing #healthcare #pharmaceutical

Ciao, amici! Are you an #EHA25 attendee? Then stop by the IMS Booth M14! We are super excited to meet you and can't wait to tell you about membership, funding opportunities, #IMS25 and even more!

Join us on Tuesday, July 1 to learn all about the top myeloma research presented at the 2025 #ASCO25, #EHA25, & #IMFIMWG meetings! This upcoming webinar on top myeloma research will focus on the patient perspective. Register today: https://mmsm.link/4kTQD1P #IMFASCO #IMFEHA

Join us virtually on 7/1 to hear the top myeloma research presented at #ASCO25, #EHA25, & #IMFIMWG! IMF CMO Dr. Joseph Mikhael will highlight & explain meeting abstracts in approachable terms that patients can use in everyday care. https://mmsm.link/4kTQD1P #IMFASCO #IMFEHA